Nevertheless, TNF-α inhibitors, which are commonly used for the treatment of IMIDs, decrease systemic inflammation and VEGF production, and thus have potential efficacy on endothelial dysfunction (56, 59, 62). The gene discussed is TNF; the disease is endothelial dysfunction.